Drug intelligence / Profile preview

Neutrox

Development stage
Unknown
Lead developer
NovaBay Pharmaceuticals
Modality
Small Molecules
Administration
Topical, Ophthalmic
01

Overview

Neutrox is a proprietary, stable formulation of 0.01% pure hypochlorous acid (HOCl) developed by NovaBay Pharmaceuticals. It serves as the active component in Avenova, a prescription-strength eyelid and eyelash cleanser. Neutrox is distinguished by its high purity and stability, remaining effective for up to three years in amber glass containers, whereas many other hypochlorous acid products contain impurities like sodium hypochlorite (bleach) that reduce shelf life and cause irritation. As a small molecule antimicrobial, Neutrox mimics the natural defense mechanism of human white blood cells (neutrophils) by producing HOCl to neutralize bacteria, viruses, and fungi, as well as the toxins they produce. It is primarily used in ophthalmology to manage conditions such as blepharitis, meibomian gland dysfunction, and dry eye syndrome by reducing the microbial load on the ocular surface without damaging sensitive tissues.

Brand names
Avenova
Other names
hypochlorous acidHOClpure hypochlorous acid

Beyond the preview

Go deeper on Neutrox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neutrox.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call